JNNP : 帕金森病患者接受丘脑下部刺激后, 短期冲动和强迫行为的预测因素

2021-10-03 Freeman MedSci原创

术前ICB严重程度较高、术前DA剂量较低的患者的ICB结果较好,而基线注意/记忆障碍较严重的患者,结果较差。

丘脑下核(STN)深部脑刺激(DBS),是晚期帕金森病(PD)患者的一种成熟的治疗方法,可改善生活质量、运动和非运动症状(NMS)。

具体来说,STN-DBS可以影响神经精神症状,如抑郁症、焦虑症、孤独症、冲动性和强迫性。目前关于DBS对冲动和强迫行为(ICB)影响的数据是对比鲜明的,有很多方法上的异质性。

据报道,PD中ICB的主要风险因素之一是多巴胺替代疗法,特别是多巴胺激动剂(DA),这可能与间叶多巴胺能系统的过度刺激有关。

由于STN-DBS通常会导致多巴胺能药物的明显减少,即降低左旋多巴等效日剂量(LEDD),所以术后ICB的改善已被观察到。然而,研究表明,STN-DBS对ICB的影响是复杂的,超越了LEDD的减少,可能的增加因素包括术前的临床方面。了解导致ICB变化的因素对于改善DBS的病人选择至关重要。


藉此, KCL的 Anna Sauerbier等人,探究了STN-DBS对ICB影响的临床预测因素。并假设,较高的术前ICB和LEDD-DA将是术后ICB有益变化的预测因素。

在这项前瞻性、开放标签、多中心的研究中,他们对接受双侧STN-DBS的PD患者进行了术前和术后6个月随访的评估。

临床量表包括PD冲动-强迫性疾病问卷-评分表(QUIP-RS)、PD问卷、非运动症状量表(NMSS)、统一PD评分表,此外还有左旋多巴当量日剂量总表(LEDD-total)和多巴胺激动剂(LEDD-DA)。随访时的变化用Wilcoxon符号秩检验进行分析,并对多重比较进行校正(Bonferroni法)。并使用相关性和线性回归探讨了QUIP-RS变化的预测因素。最后,他们将患者分为 "QUIP-RS改善或恶化 "两类,并分析组间差异。

他们纳入了55名患者,年龄为61.7岁±8.4岁,PD病程为9.8年±4.6年。QUIP-RS临界值和精神评估确定了术前ICB的患者。在患有ICB的患者中,QUIP-RS明显改善。

然而,他们观察到临床相关的QUIP-RS结果有相当大的个体差异,因为27.3%的患者病情恶化,29.1%的患者病情改善。

在post-hoc分析中,较高的基线QUIP-RS和较低的基线LEDD-DA与较大的QUIP-RS改善有关。此外,"QUIP-RS恶化 "组在NMSS注意/记忆领域有更严重的基线损伤。

这个研究的核心结论是:术前ICB严重程度较高、术前DA剂量较低的患者的ICB结果较好,而基线注意/记忆障碍较严重的患者的结果较差。这些发现强调了对接受STN-DBS的病人进行全面的非运动和运动症状评估的必要性。


原文出处:
Sauerbier A, Loehrer P, Jost ST, et al. Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry. Published online September 11, 2021:jnnp-2021-326131. doi:10.1136/jnnp-2021-326131

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757442, encodeId=bc341e574429e, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Tue May 17 17:49:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264376, encodeId=71e412643e67c, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558344, encodeId=1c21155834411, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564353, encodeId=1c171564353c0, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573955, encodeId=3f5715e3955f1, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757442, encodeId=bc341e574429e, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Tue May 17 17:49:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264376, encodeId=71e412643e67c, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558344, encodeId=1c21155834411, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564353, encodeId=1c171564353c0, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573955, encodeId=3f5715e3955f1, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757442, encodeId=bc341e574429e, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Tue May 17 17:49:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264376, encodeId=71e412643e67c, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558344, encodeId=1c21155834411, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564353, encodeId=1c171564353c0, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573955, encodeId=3f5715e3955f1, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-10-05 xlwang2696
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757442, encodeId=bc341e574429e, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Tue May 17 17:49:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264376, encodeId=71e412643e67c, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558344, encodeId=1c21155834411, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564353, encodeId=1c171564353c0, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573955, encodeId=3f5715e3955f1, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-10-05 xlwang2696
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757442, encodeId=bc341e574429e, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Tue May 17 17:49:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264376, encodeId=71e412643e67c, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558344, encodeId=1c21155834411, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564353, encodeId=1c171564353c0, content=<a href='/topic/show?id=c8a7208e8a8' target=_blank style='color:#2F92EE;'>#丘脑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20878, encryptionId=c8a7208e8a8, topicName=丘脑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb8814960000, createdName=xlwang2696, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573955, encodeId=3f5715e3955f1, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Tue Oct 05 16:49:31 CST 2021, time=2021-10-05, status=1, ipAttribution=)]

相关资讯

Neurology:帕金森病患者对步态损害补偿策略的认知与使用

研究人员对4324名患有帕金森病和自我报告的致残步态障碍的成年人进行调查。帕金森病患者步态损害补偿策略的选择应针对个体患者,以及需要应用该策略的环境。

JNNP:帕金森病患者与视幻觉相关的丘脑白质和灰质纵向变化

视幻觉(VH)在帕金森病(PD)中很常见,可对受影响的个体及其家人造成严重的痛苦,造成更坏的结果:帕金森病和视幻觉患者的生活质量较差,死亡率增加,随后痴呆的发生率更高。PD相关幻觉伴随着脑网络失衡,脑

Neurology:肉毒毒素治疗后皮质兴奋性和帕金森震颤的变化

近日有研究人员探讨A型肉毒毒素(BoNT-A)给药、震颤幅度、双脉冲经颅磁刺激(pp-TMS)对皮层内兴奋性和感觉运动加工的调节作用与早期震颤症型帕金森病(PD)患者的关系。

Mov Disord : 新型左旋多巴肠道凝胶,可有效减缓帕金森的运动障碍表现

左旋多巴-卡比多巴的组合是帕金森病(PD)治疗的主流。一般来说,儿茶酚-O-甲基转移酶(COM-T)抑制剂、单胺氧化酶-B(MAO-B)抑制剂和多巴胺激动剂与左旋多巴同时使用以减少运动波动。尽管使用了

Mov Disord : 利用纵向数据,可更有效预测帕金森患者预后

纳入多种临床措施的纵向信息可显著提高预后模型的预测性能。

JNNP:丘脑的灰白质改变,可反映帕金森患者的视幻觉

随着时间的推移,皮层厚度相对保存下来。右侧丘脑内侧核在PD幻觉者中显示出连接和体积损失。

拓展阅读

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

European Radiology:弥散基础频谱成像检测早期帕金森病黑质和白质束的病理改变

为了解决弥散张量成像的局限性,研究发展了弥散基谱成像 (DBSI)以粗量化各向异性扩散张量反映轴突的完整性,其在多种中枢神经系统疾病中的敏感性和准确性已被证实。

帕金森病睡眠量表修订版(PDSS-2)

帕金森病睡眠量表修订版(PDSS-2)

神经科一周速递:热点解读进展大盘点!

一周热点分享 ,紧跟神经科学前沿,让每一次诊疗都更精准,点击立即查看!

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10